On-demand programs deliver clinically relevant science, technical instruction, and case applications in small animal and equine practice MINNEAPOLIS, Sept. 25, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, a subsidiary of PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and a veterinary medical device company pioneering intra-articular and regenerative solutions, announces the launch of three new continuing education (CE) courses for veterinary professionals. Each RACE-approved program (1.0 credit hour) ...

Summary of PetVivo Holdings Conference Call Company Overview - **Company Name**: PetVivo Holdings - **Ticker Symbol**: PETV - **Market Focus**: Companion animal veterinary care market, valued at approximately $11 billion [2][19] Core Products - **Spryng with OsteoCushion Technology**: A veterinary medical device designed to restore joint mechanics and address osteoarthritis in animals. It is classified as a human medical device, allowing it to bypass FDA review for veterinary use [2][8]. - **PrecisePRP**: An allogenic freeze-dried platelet-rich plasma product, the only FDA-reviewed product for safety that does not require blood drawing from the animal [2][17]. Market Dynamics - **Osteoarthritis Prevalence**: Approximately 80% of dogs will develop osteoarthritis by age eight, with symptoms often starting as early as three to four years old [4]. - **Current Treatment Limitations**: Existing treatments primarily mask symptoms rather than address the root cause, leading to potential long-term damage [5][12]. Competitive Advantages - **Unique Mechanism of Action**: Spryng addresses the underlying issues of joint degradation rather than just alleviating pain, providing a longer-lasting solution (up to 12 months) compared to other treatments [6][8]. - **Cost-Effectiveness**: Spryng's pricing ranges from $600 to $1,200 per injection, which is competitive compared to monthly treatments like Librela costing around $150 [31][32]. - **Strong Intellectual Property Portfolio**: PetVivo holds 12 U.S. patents and 9 foreign patents, with ongoing efforts to expand this portfolio [3][9]. Distribution and Expansion - **Distribution Agreements**: Established partnerships with major distributors in the U.S. and recent expansions into Mexico and the UK [3][27]. - **Market Growth**: The pet care market is considered recession-proof, with increasing spending on veterinary care as pets are viewed as family members [19]. Clinical Evidence and Studies - **Successful Clinical Trials**: Over 12,000 injections have been administered with positive outcomes, including a study showing a 77% improvement in dogs with late-stage hip issues [10][15][16]. - **Ongoing Research**: Multiple clinical trials are underway, including studies at Colorado State University, aimed at further validating the efficacy of Spryng [16][24]. Future Outlook - **Product Pipeline**: Plans to expand into human markets and develop additional veterinary applications [22][29]. - **Regulatory Support**: The product has received endorsements from regulatory bodies, enhancing its credibility in the market [28]. Management and Team - **Experienced Leadership**: The management team includes individuals with extensive backgrounds in both veterinary and human healthcare sectors, contributing to the company's strategic direction [26][27]. Conclusion PetVivo Holdings is positioned to capitalize on the growing demand for effective veterinary treatments, particularly for osteoarthritis, through its innovative products and strong market presence. The company aims to leverage its unique technology and distribution partnerships to drive future growth and expand into new markets.

Core Points - PetVivo Animal Health, Inc. has entered into a distribution agreement with Nupsala Limited to market its veterinary medical device, Spryng with OsteoCushion technology, in the United Kingdom [1][2] - The distribution activities by Nupsala commenced on September 1, 2025, aiming to enhance the accessibility of Spryng to veterinarians and animal owners [1][2] - Spryng with OsteoCushion technology is designed to manage joint pain in animals by promoting proper joint mechanics and integrating with subsynovial tissue [3][4] Company Overview - PetVivo Holdings, Inc. focuses on the commercialization of innovative medical devices and therapeutics for companion animals, leveraging human therapies for efficient treatment [5] - The company has a robust pipeline of products, including Spryng and PrecisePRP, and holds a portfolio of twenty-one patents protecting its biomaterials and methods [6] Partner Overview - Nupsala Limited specializes in musculoskeletal health and regenerative medicine for companion animals and horses, operating as both a veterinary wholesaler and referral provider [8][9] - Nupsala aims to improve animal mobility and deliver innovative solutions through clinical trials, diagnostics, and educational initiatives [9]